ClinVar Genomic variation as it relates to human health
Help
- Interpretation:
-
Conflicting interpretations of pathogenicity; other
Likely pathogenic(1); Uncertain significance(1); Benign(6); Likely benign(1)
- Review status:
- criteria provided, conflicting interpretations
- Submissions:
- 19
- First in ClinVar:
- Nov 13, 2014
- Most recent Submission:
- Nov 20, 2023
- Last evaluated:
- Sep 7, 2023
- Accession:
- VCV000003521.114
- Variation ID:
- 3521
- Description:
- single nucleotide variant
Help
NM_005957.5(MTHFR):c.1286A>C (p.Glu429Ala)
- Allele ID
- 18560
- Variant type
- single nucleotide variant
- Variant length
- 1 bp
- Cytogenetic location
- 1p36.22
- Genomic location
- 1: 11794419 (GRCh38) GRCh38 UCSC
- 1: 11854476 (GRCh37) GRCh37 UCSC
- HGVS
-
Nucleotide Protein Molecular
consequenceNM_005957.5:c.1286A>C MANE Select NP_005948.3:p.Glu429Ala missense NM_001330358.2:c.1409A>C NP_001317287.1:p.Glu470Ala missense NC_000001.11:g.11794419T>G NC_000001.10:g.11854476T>G NG_013351.1:g.16685A>C LRG_726:g.16685A>C LRG_726t1:c.1286A>C LRG_726p1:p.Glu429Ala P42898:p.Glu429Ala - Protein change
- E470A
- Other names
- MTHFR, 1298A-C, GLU429ALA (rs1801131)
- E429A
- Canonical SPDI
- NC_000001.11:11794418:T:G
- Functional consequence
- -
- Global minor allele frequency (GMAF)
- 0.24940 (G)
- Allele frequency
- Trans-Omics for Precision Medicine (TOPMed) 0.24615
- NHLBI Exome Sequencing Project (ESP) Exome Variant Server 0.25957
- Trans-Omics for Precision Medicine (TOPMed) 0.24909
- The Genome Aggregation Database (gnomAD) 0.26038
- The Genome Aggregation Database (gnomAD), exomes 0.28900
- 1000 Genomes Project 0.24940
- The Genome Aggregation Database (gnomAD) 0.25830
- Exome Aggregation Consortium (ExAC) 0.29500
- Links
- Genetic Testing Registry (GTR): GTR000500035
- Genetic Testing Registry (GTR): GTR000500809
- Genetic Testing Registry (GTR): GTR000562560
- Genetic Testing Registry (GTR): GTR000593372
- UniProtKB: P42898#VAR_014882
- OMIM: 607093.0004
- dbSNP: rs1801131
- PharmGKB Clinical Annotation: 1183705832
- ClinGen: CA116320
- VarSome
Help
Aggregate interpretations per condition
Interpreted condition | Interpretation | Number of submissions | Review status | Last evaluated | Variation/condition record |
---|---|---|---|---|---|
risk factor | 1 | no assertion criteria provided | Jul 1, 2008 | RCV000003699.12 | |
Benign | 1 | no assertion criteria provided | Jul 1, 2008 | RCV000003698.12 | |
Uncertain significance | 1 | no assertion criteria provided | - | RCV000144922.9 | |
Benign; other | 4 | criteria provided, multiple submitters, no conflicts | Jul 1, 2023 | RCV000153515.33 | |
Benign | 1 | criteria provided, single submitter | May 28, 2019 | RCV000350590.11 | |
Likely benign | 6 | criteria provided, single submitter | Sep 7, 2023 | RCV000430863.20 | |
Conflicting interpretations of pathogenicity | 4 | criteria provided, conflicting interpretations | Nov 4, 2022 | RCV001197542.16 | |
Uncertain significance | 1 | criteria provided, single submitter | Jun 23, 2021 | RCV002227013.9 |
Submitted interpretations and evidence
HelpInterpretation (Last evaluated) |
Review status (Assertion criteria) |
Condition (Inheritance) |
Submitter | More information | |
---|---|---|---|---|---|
Benign
(May 28, 2019)
|
criteria provided, single submitter
Method: clinical testing
|
Affected status: unknown
Allele origin:
unknown
|
Mendelics
Accession: SCV001135170.1
First in ClinVar: Jan 09, 2020 Last updated: Jan 09, 2020 |
|
|
Likely pathogenic
(Jan 28, 2019)
|
criteria provided, single submitter
Method: clinical testing
|
Affected status: yes
Allele origin:
unknown
|
Centre for Mendelian Genomics, University Medical Centre Ljubljana
Accession: SCV001368321.2
First in ClinVar: Jul 06, 2020 Last updated: Jul 06, 2020 |
Comment:
This variant was classified as: Likely pathogenic. The following ACMG criteria were applied in classifying this variant: No criteria apply. This variant was detected in … (more)
This variant was classified as: Likely pathogenic. The following ACMG criteria were applied in classifying this variant: No criteria apply. This variant was detected in homozygous state. (less)
|
|
Benign
(Jul 01, 2021)
|
criteria provided, single submitter
Method: clinical testing
|
Affected status: no
Allele origin:
germline
|
Genome-Nilou Lab
Accession: SCV001748535.1
First in ClinVar: Jul 10, 2021 Last updated: Jul 10, 2021 |
Sex: mixed
|
|
Benign
(Feb 25, 2021)
|
criteria provided, single submitter
Method: clinical testing
|
Affected status: yes
Allele origin:
germline
|
GeneDx
Accession: SCV000519507.4
First in ClinVar: Mar 08, 2017 Last updated: Mar 08, 2017 |
Comment:
E429A, commonly reported as c.1298A>C, is a benign variant. It results in reduced MTHFR activity but it is not associated with increased plasma folate concentration … (more)
E429A, commonly reported as c.1298A>C, is a benign variant. It results in reduced MTHFR activity but it is not associated with increased plasma folate concentration in the heterozygous or homozygous state. This variant is present in 31% of alleles in large population cohorts (Lek et al., 2016); This variant is associated with the following publications: (PMID: 9545395, 18842806, 21241403, 22882325, 18836720, 21577095, 20135343, 23652803, 18992148, 23162020, 23771968, 19936946, 19837268, 20031554, 19232336, 19356065, 11875032, 22102315, 21897766, 21334398, 21845428, 20935396, 20532637, 21080081, 18583979, 21613384, 19854238, 21107737, 11395038, 9719624, 26238013, 27068821, 27330833, 23659764, 24109560, 23685927, 11274424, 29600437, 24440586, 22051736, 29395581, 20078877, 24175756, 24488901, 24301776, 22576927, 25573130, 29974397, 26135458, 23523621, 16489479) (less)
|
|
Benign
(Nov 04, 2022)
|
criteria provided, single submitter
Method: clinical testing
|
Affected status: unknown
Allele origin:
germline
|
Invitae
Accession: SCV001733272.2
First in ClinVar: Jun 15, 2021 Last updated: Mar 26, 2023 |
|
|
Likely benign
(Sep 07, 2023)
|
criteria provided, single submitter
Method: clinical testing
|
Affected status: unknown
Allele origin:
germline
|
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Accession: SCV004099611.1
First in ClinVar: Nov 04, 2023 Last updated: Nov 04, 2023 |
Comment:
Variant summary: MTHFR c.1286A>C (p.Glu429Ala) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a benign … (more)
Variant summary: MTHFR c.1286A>C (p.Glu429Ala) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.29 in 251462 control chromosomes in the gnomAD database, including 11567 homozygotes strongly suggesting that the variant is benign. This variant, c.1286A>C is also known as 1298A>C. One publication reports experimental evidence evaluating an impact on protein function. The most pronounced variant effect results in >50%-90% of normal activity and homocysteine levels for heterozygotes and homozygotes were not different from those with the wild type genotype, supporting the idea that this polymorphism alone might not significantly affect homocysteine metabolism (example: Weisberg_2001). The following publication has been ascertained in the context of this evaluation (PMID: 11395038). Ten submitters have cited clinical-significance assessments for this variant to ClinVar after 2014 and classified the variant as Benign/likely benign (n=7), uncertain significance (n=1), risk factor (n=1) and likely pathogenic (n=1). Based on the evidence outlined above, the variant was classified as likely benign. (less)
|
|
other
(Jan 13, 2017)
|
criteria provided, single submitter
Method: clinical testing
|
Affected status: unknown
Allele origin:
germline
|
Eurofins Ntd Llc (ga)
Accession: SCV000203039.7
First in ClinVar: Feb 02, 2015 Last updated: Dec 06, 2016 |
Number of individuals with the variant: 169
Zygosity: 32 Homozygote, 134 Single Heterozygote
Sex: mixed
|
|
Uncertain significance
(Jun 23, 2021)
|
criteria provided, single submitter
Method: clinical testing
|
Affected status: yes
Allele origin:
germline
|
Institute of Human Genetics, University Hospital Muenster
Accession: SCV002506414.1
First in ClinVar: May 07, 2022 Last updated: May 07, 2022 |
Comment:
ACMG categories: PS3,PS4,PM1,BA1
Number of individuals with the variant: 1
Clinical Features:
Stroke (present)
Zygosity: 1 Compound Heterozygote
Age: 10-19 years
Sex: male
Tissue: blood
|
|
Benign
(Oct 25, 2022)
|
criteria provided, single submitter
Method: clinical testing
|
Affected status: unknown
Allele origin:
germline
|
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories
Accession: SCV000604289.7
First in ClinVar: Mar 08, 2017 Last updated: Mar 04, 2023 |
|
|
Benign
(Jul 01, 2023)
|
criteria provided, single submitter
Method: clinical testing
|
Affected status: yes
Allele origin:
germline
|
CeGaT Center for Human Genetics Tuebingen
Accession: SCV001147148.16
First in ClinVar: Feb 03, 2020 Last updated: Nov 20, 2023 |
Comment:
Criteria applied: BP4, BS1, BS2
Number of individuals with the variant: 4
|
|
Uncertain significance
(-)
|
no assertion criteria provided
Method: case-control
|
Affected status: yes
Allele origin:
germline
|
Department of Pharmacy and Biotechnology, University of Bologna
Accession: SCV000187679.1
First in ClinVar: Nov 13, 2014 Last updated: Nov 13, 2014 |
Number of individuals with the variant: 36
Zygosity: 8 Homozygote, 28 Single Heterozygote
|
|
Benign
(Jul 01, 2008)
|
no assertion criteria provided
Method: literature only
|
Affected status: not provided
Allele origin:
germline
|
OMIM
Accession: SCV000023861.3
First in ClinVar: Apr 04, 2013 Last updated: Dec 31, 2017 |
Comment on evidence:
Van der Put et al. (1998) identified another polymorphism of the MTHFR gene: a 1298A-C mutation resulting in a glu429-to-ala (E429A) substitution. The mutation destroyed … (more)
Van der Put et al. (1998) identified another polymorphism of the MTHFR gene: a 1298A-C mutation resulting in a glu429-to-ala (E429A) substitution. The mutation destroyed an MboII recognition site and had an allele frequency of 0.33. Whereas the 677C-T transition (607093.0003) occurs within the predicted catalytic domain of the MTHFR enzyme, the 1298A-C transversion is located in the presumed regulatory domain. The 1298A-C mutation resulted in decreased MTHFR activity, which was more pronounced in the homozygous than heterozygous state. Neither the homozygous nor the heterozygous state was associated with higher plasma homocysteine (Hcy) nor a lower plasma folate concentration--phenomena that are evident with homozygosity for the 677C-T mutation. However, van der Put et al. (1998) found that combined heterozygosity at the 2 polymorphic sites was associated with reduced MTHFR-specific activity, higher Hcy, and decreased plasma folate levels. Thus, combined heterozygosity for both MTHFR mutations resulted in features similar to those observed in homozygotes for the 677C-T mutation. This combined heterozygosity was observed in 28% of the neural tube defect (NTD) patients compared with 20% among controls, resulting in an odds ratio of 2.04. The data suggested that combined heterozygosity for the 2 common mutations accounts for a proportion of folate-related NTDs, which is not explained by homozygosity for the 677C-T mutation. Yamada et al. (2001) studied the biochemical characteristics of the products of both the 677C-T and the 1298A-C polymorphisms by overexpressing the genes and purifying the protein to homogeneity in quantities suitable for the characterization. The E429A protein had biochemical properties indistinguishable from the wildtype enzyme. The A222V MTHFR, however, had an enhanced propensity to dissociate into monomers and to lose its FAD cofactor on dilution. Protein that had both changes revealed no additive effect in these biochemical studies. This prompted Scott (2001) to suggest that the claim of van der Put et al. (1998) that the double variant increases risk needed to be reevaluated. Donnelly (2000) argued that the change described by van der Put et al. (1998) as 1298A-C is in fact 1289A-C. The mutation was expected to change the codon from GAA (glu) to GCA (ala). In a reply to Donnelly (2000), van der Put and Blom (2000) stated that the second SNP was designated 1298A-C for consistency with the first SNP, 677C-T. Although the first SNP was said to occur at nucleotide 677, the actual location may be nucleotide 665 of the coding region. Isotalo et al. (2000) analyzed 119 neonatal cord blood samples and 161 fetal tissue samples for MTHFR 677C-T and 1298A-C mutations to determine whether certain MTHFR genotype combinations were associated with decreased in utero viability. Mutation analysis demonstrated that all possible MTHFR genotype combinations were represented in the fetal group; 677T and 1298C alleles could occur in either cis or trans configurations. Combined 677CT/1298CC and 677TT/1298CC genotypes, which contained 3 and 4 mutant alleles, respectively, were not observed in the neonatal group (p = 0.0402). This suggested decreased viability among fetuses carrying these mutations and a possible selection disadvantage among fetuses with increased numbers of mutant MTHFR alleles. This was the first report to describe the existence of human MTHFR 677CT/1298CC and 677TT/1298CC genotypes and demonstrated their potential role in compromised fetal viability. Volcik et al. (2001) presented data supporting the conclusion of Isotalo et al. (2000) concerning decreased viability among fetuses with the 677TT/1298CC genotype, which they did not observe in the United States and Canadian populations studied. Because they observed, in 3 different populations, the 677CT/1298CC genotype in frequencies nearing those expected, Volcik et al. (2001) concluded that this genotype does not result in a significant selective disadvantage. Zetterberg et al. (2002) examined the distribution of the 677C-T and 1298A-C polymorphisms in 80 fetal tissue samples from spontaneous abortions occurring between the sixth and twentieth week of pregnancy, compared to 125 healthy blood donors (both cases and controls were from Crete, Greece). Only 1 of the 80 spontaneously aborted embryos had the wildtype combined genotype 677CC/1298AA as compared to 19 of 125 controls (p = 0.001). Combined genotypes which contain 3 or 4 mutant alleles were not detected in any of the groups, suggesting complete linkage disequilibrium between the 2 polymorphisms. A significant odds ratio of 14.2 (95% CI, 1.78-113) for spontaneous abortion was obtained when comparing the prevalence of at least 1 MTHFR mutation in abortions and controls (p = 0.001). Zetterberg et al. (2002) concluded from the data that the effect of 1 or more MTHFR mutated alleles may be detrimental during embryogenesis when the folate requirement is high. Both the 677C-T and 1298A-C SNPs in the MTHFR gene decrease the activity of the enzyme, leading to hyperhomocysteinemia (603174), particularly in folate-deficient states. Ogino and Wilson (2003) calculated the haplotype frequencies of the polymorphisms at nucleotides 677 and 1298 in pooled general populations derived from data published in 16 articles. They found that most 677T and 1298C alleles were associated with 1298A and 677C alleles, respectively. There may be an increased frequency of the very rare cis 677T/1298C haplotype in some parts of the United Kingdom and Canada, possibly due to a founder effect. Among Turkish women, Boduroglu et al. (2004) could find no support for a relationship between the 677C-T and 1298A-C SNPs in the MTHFR gene and risk of having a child with Down syndrome (190685). Among 200 Indian individuals, Kumar et al. (2005) found that plasma homocysteine levels were significantly increased in those adhering to a vegetarian diet and in those with a 1298C allele. However, the increase in homocysteine levels in vegetarians was irrespective of MTHFR genotype. Among a larger group of over 400 Indian individuals, Kumar et al. (2005) found that the frequency of the 1298CC genotype was 19.46%, which was much higher than that reported for Caucasian (9.4%), Chinese (3.3%), or Japanese (1.6%) populations. The authors concluded that the 1298A-C polymorphism is relevant for increased plasma homocysteine levels in the Indian population. Hobbs et al. (2006) observed an apparent protective effect of the MTHFR 1298C allele against congenital heart defect. Allen et al. (2008) performed a metaanalysis comparing 1,211 cases of schizophrenia with 1,729 controls and found that the MTHFR 1298C allele (1801133) was associated with susceptibility to schizophrenia (odds ratio, 1.19; 95% CI, 1.07- 1.34; p = 0.002). According to the Venice guidelines for the assessment of cumulative evidence in genetic association studies (Ioannidis et al., 2008), the MTHFR association showed a 'strong' degree of epidemiologic credibility. (less)
|
|
risk factor
(Jul 01, 2008)
|
no assertion criteria provided
Method: literature only
|
Affected status: not provided
Allele origin:
germline
|
OMIM
Accession: SCV000023862.3
First in ClinVar: Apr 04, 2013 Last updated: Dec 31, 2017 |
Comment on evidence:
Van der Put et al. (1998) identified another polymorphism of the MTHFR gene: a 1298A-C mutation resulting in a glu429-to-ala (E429A) substitution. The mutation destroyed … (more)
Van der Put et al. (1998) identified another polymorphism of the MTHFR gene: a 1298A-C mutation resulting in a glu429-to-ala (E429A) substitution. The mutation destroyed an MboII recognition site and had an allele frequency of 0.33. Whereas the 677C-T transition (607093.0003) occurs within the predicted catalytic domain of the MTHFR enzyme, the 1298A-C transversion is located in the presumed regulatory domain. The 1298A-C mutation resulted in decreased MTHFR activity, which was more pronounced in the homozygous than heterozygous state. Neither the homozygous nor the heterozygous state was associated with higher plasma homocysteine (Hcy) nor a lower plasma folate concentration--phenomena that are evident with homozygosity for the 677C-T mutation. However, van der Put et al. (1998) found that combined heterozygosity at the 2 polymorphic sites was associated with reduced MTHFR-specific activity, higher Hcy, and decreased plasma folate levels. Thus, combined heterozygosity for both MTHFR mutations resulted in features similar to those observed in homozygotes for the 677C-T mutation. This combined heterozygosity was observed in 28% of the neural tube defect (NTD) patients compared with 20% among controls, resulting in an odds ratio of 2.04. The data suggested that combined heterozygosity for the 2 common mutations accounts for a proportion of folate-related NTDs, which is not explained by homozygosity for the 677C-T mutation. Yamada et al. (2001) studied the biochemical characteristics of the products of both the 677C-T and the 1298A-C polymorphisms by overexpressing the genes and purifying the protein to homogeneity in quantities suitable for the characterization. The E429A protein had biochemical properties indistinguishable from the wildtype enzyme. The A222V MTHFR, however, had an enhanced propensity to dissociate into monomers and to lose its FAD cofactor on dilution. Protein that had both changes revealed no additive effect in these biochemical studies. This prompted Scott (2001) to suggest that the claim of van der Put et al. (1998) that the double variant increases risk needed to be reevaluated. Donnelly (2000) argued that the change described by van der Put et al. (1998) as 1298A-C is in fact 1289A-C. The mutation was expected to change the codon from GAA (glu) to GCA (ala). In a reply to Donnelly (2000), van der Put and Blom (2000) stated that the second SNP was designated 1298A-C for consistency with the first SNP, 677C-T. Although the first SNP was said to occur at nucleotide 677, the actual location may be nucleotide 665 of the coding region. Isotalo et al. (2000) analyzed 119 neonatal cord blood samples and 161 fetal tissue samples for MTHFR 677C-T and 1298A-C mutations to determine whether certain MTHFR genotype combinations were associated with decreased in utero viability. Mutation analysis demonstrated that all possible MTHFR genotype combinations were represented in the fetal group; 677T and 1298C alleles could occur in either cis or trans configurations. Combined 677CT/1298CC and 677TT/1298CC genotypes, which contained 3 and 4 mutant alleles, respectively, were not observed in the neonatal group (p = 0.0402). This suggested decreased viability among fetuses carrying these mutations and a possible selection disadvantage among fetuses with increased numbers of mutant MTHFR alleles. This was the first report to describe the existence of human MTHFR 677CT/1298CC and 677TT/1298CC genotypes and demonstrated their potential role in compromised fetal viability. Volcik et al. (2001) presented data supporting the conclusion of Isotalo et al. (2000) concerning decreased viability among fetuses with the 677TT/1298CC genotype, which they did not observe in the United States and Canadian populations studied. Because they observed, in 3 different populations, the 677CT/1298CC genotype in frequencies nearing those expected, Volcik et al. (2001) concluded that this genotype does not result in a significant selective disadvantage. Zetterberg et al. (2002) examined the distribution of the 677C-T and 1298A-C polymorphisms in 80 fetal tissue samples from spontaneous abortions occurring between the sixth and twentieth week of pregnancy, compared to 125 healthy blood donors (both cases and controls were from Crete, Greece). Only 1 of the 80 spontaneously aborted embryos had the wildtype combined genotype 677CC/1298AA as compared to 19 of 125 controls (p = 0.001). Combined genotypes which contain 3 or 4 mutant alleles were not detected in any of the groups, suggesting complete linkage disequilibrium between the 2 polymorphisms. A significant odds ratio of 14.2 (95% CI, 1.78-113) for spontaneous abortion was obtained when comparing the prevalence of at least 1 MTHFR mutation in abortions and controls (p = 0.001). Zetterberg et al. (2002) concluded from the data that the effect of 1 or more MTHFR mutated alleles may be detrimental during embryogenesis when the folate requirement is high. Both the 677C-T and 1298A-C SNPs in the MTHFR gene decrease the activity of the enzyme, leading to hyperhomocysteinemia (603174), particularly in folate-deficient states. Ogino and Wilson (2003) calculated the haplotype frequencies of the polymorphisms at nucleotides 677 and 1298 in pooled general populations derived from data published in 16 articles. They found that most 677T and 1298C alleles were associated with 1298A and 677C alleles, respectively. There may be an increased frequency of the very rare cis 677T/1298C haplotype in some parts of the United Kingdom and Canada, possibly due to a founder effect. Among Turkish women, Boduroglu et al. (2004) could find no support for a relationship between the 677C-T and 1298A-C SNPs in the MTHFR gene and risk of having a child with Down syndrome (190685). Among 200 Indian individuals, Kumar et al. (2005) found that plasma homocysteine levels were significantly increased in those adhering to a vegetarian diet and in those with a 1298C allele. However, the increase in homocysteine levels in vegetarians was irrespective of MTHFR genotype. Among a larger group of over 400 Indian individuals, Kumar et al. (2005) found that the frequency of the 1298CC genotype was 19.46%, which was much higher than that reported for Caucasian (9.4%), Chinese (3.3%), or Japanese (1.6%) populations. The authors concluded that the 1298A-C polymorphism is relevant for increased plasma homocysteine levels in the Indian population. Hobbs et al. (2006) observed an apparent protective effect of the MTHFR 1298C allele against congenital heart defect. Allen et al. (2008) performed a metaanalysis comparing 1,211 cases of schizophrenia with 1,729 controls and found that the MTHFR 1298C allele (1801133) was associated with susceptibility to schizophrenia (odds ratio, 1.19; 95% CI, 1.07- 1.34; p = 0.002). According to the Venice guidelines for the assessment of cumulative evidence in genetic association studies (Ioannidis et al., 2008), the MTHFR association showed a 'strong' degree of epidemiologic credibility. (less)
|
|
Benign
(-)
|
no assertion criteria provided
Method: clinical testing
|
Affected status: yes
Allele origin:
germline
|
Genome Diagnostics Laboratory, University Medical Center Utrecht
Additional submitter:
Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen
Study: VKGL Data-share Consensus
Accession: SCV001928366.1 First in ClinVar: Sep 26, 2021 Last updated: Sep 26, 2021 |
|
|
Benign
(-)
|
no assertion criteria provided
Method: clinical testing
|
Affected status: yes
Allele origin:
germline
|
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+
Additional submitter:
Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen
Study: VKGL Data-share Consensus
Accession: SCV001956936.1 First in ClinVar: Oct 02, 2021 Last updated: Oct 02, 2021 |
|
|
Benign
(-)
|
no assertion criteria provided
Method: clinical testing
|
Affected status: yes
Allele origin:
germline
|
Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center
Additional submitter:
Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen
Study: VKGL Data-share Consensus
Accession: SCV002037998.1 First in ClinVar: Dec 25, 2021 Last updated: Dec 25, 2021 |
|
|
Benign
(Sep 16, 2020)
|
no assertion criteria provided
Method: clinical testing
|
Affected status: unknown
Allele origin:
germline
|
Natera, Inc.
Accession: SCV001455754.1
First in ClinVar: Jan 02, 2021 Last updated: Jan 02, 2021 |
|
|
Benign
(-)
|
no assertion criteria provided
Method: clinical testing
|
Affected status: yes
Allele origin:
germline
|
Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen
Study: VKGL Data-share Consensus
Accession: SCV001741945.3 First in ClinVar: Jul 07, 2021 Last updated: Sep 08, 2021 |
|
|
Benign
(-)
|
no assertion criteria provided
Method: clinical testing
|
Affected status: yes
Allele origin:
germline
|
Clinical Genetics, Academic Medical Center
Additional submitter:
Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen
Study: VKGL Data-share Consensus
Accession: SCV001919429.1 First in ClinVar: Sep 26, 2021 Last updated: Sep 26, 2021 |
|
Functional evidence
HelpThere is no functional evidence in ClinVar for this variation. If you have generated functional data for this variation, please consider submitting that data to ClinVar. |
Citations for this variant
HelpTitle | Author | Journal | Year | Link |
---|---|---|---|---|
The communal relation of MTHFR, MTR, ACE gene polymorphisms and hyperhomocysteinemia as conceivable risk of coronary artery disease. | Masud R | Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme | 2017 | PMID: 28514598 |
Folate-related polymorphisms in gastrointestinal stromal tumours: susceptibility and correlation with tumour characteristics and clinical outcome. | Angelini S | European journal of human genetics : EJHG | 2015 | PMID: 25227144 |
Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. | Allen NC | Nature genetics | 2008 | PMID: 18583979 |
Congenital heart defects and genetic variants in the methylenetetrahydroflate reductase gene. | Hobbs CA | Journal of medical genetics | 2006 | PMID: 15951337 |
Homocysteine levels are associated with MTHFR A1298C polymorphism in Indian population. | Kumar J | Journal of human genetics | 2005 | PMID: 16244782 |
'Racial' differences in genetic effects for complex diseases. | Ioannidis JP | Nature genetics | 2004 | PMID: 15543147 |
Methylenetetrahydrofolate reductase enzyme polymorphisms as maternal risk for Down syndrome among Turkish women. | Boduroğlu K | American journal of medical genetics. Part A | 2004 | PMID: 15103709 |
Genotype and haplotype distributions of MTHFR677C>T and 1298A>C single nucleotide polymorphisms: a meta-analysis. | Ogino S | Journal of human genetics | 2003 | PMID: 12560871 |
Increased frequency of combined methylenetetrahydrofolate reductase C677T and A1298C mutated alleles in spontaneously aborted embryos. | Zetterberg H | European journal of human genetics : EJHG | 2002 | PMID: 11938441 |
Genetic diversity and disease: opportunities and challenge. | Scott JM | Proceedings of the National Academy of Sciences of the United States of America | 2001 | PMID: 11752418 |
Effects of common polymorphisms on the properties of recombinant human methylenetetrahydrofolate reductase. | Yamada K | Proceedings of the National Academy of Sciences of the United States of America | 2001 | PMID: 11742092 |
Examinations of methylenetetrahydrofolate reductase C677T and A1298C mutations--and in utero viability. | Volcik KA | American journal of human genetics | 2001 | PMID: 11590551 |
The 1298A-->C polymorphism in methylenetetrahydrofolate reductase (MTHFR): in vitro expression and association with homocysteine. | Weisberg IS | Atherosclerosis | 2001 | PMID: 11395038 |
Neonatal and fetal methylenetetrahydrofolate reductase genetic polymorphisms: an examination of C677T and A1298C mutations. | Isotalo PA | American journal of human genetics | 2000 | PMID: 10958762 |
The 1298(A-->C) mutation of methylenetetrahydrofolate reductase should be designated to the 1289 position of the gene. | Donnelly JG | American journal of human genetics | 2000 | PMID: 10677336 |
A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? | van der Put NM | American journal of human genetics | 1998 | PMID: 9545395 |
http://www.egl-eurofins.com/emvclass/emvclass.php?approved_symbol=MTHFR | - | - | - | - |
van der Put, N. M. J., Blom, H. J. Reply to Donnelly. (Letter) Am. J. Hum. Genet. 66: 744-745, 2000. | - | - | - | - |
Text-mined citations for rs1801131...
HelpThese citations are identified by LitVar using
the rs number, so they may include citations for more than one variant
at this location. Please review the LitVar results carefully for your
variant of interest.
Record last updated Nov 25, 2023